[Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]. - Publication

Publication

[Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics].

Journal Paper/Review - Dec 14, 2022

Popp Julius, Georgescu Dan, Bürge Markus, Mundwiler-Pachlatko Esther, Bernasconi Luca, Felbecker Ansgar

Citation

Popp J, Georgescu D, Bürge M, Mundwiler-Pachlatko E, Bernasconi L, Felbecker A. [Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]. Rev Med Suisse 2022; 18:2400-2405.

Type

Journal Paper/Review (English)

Journal

Rev Med Suisse 2022; 18

Publication Date

Dec 14, 2022

Issn Print

1660-9379

Pages

2400-2405

Brief description/objective

Established cerebrospinal fluid (CSF) biomarkers allow for earlier and more accurate etiological diagnosis of cognitive impairment. Information and counselling are needed both before and after biomarker-supported diagnosis. The procedures for diagnostic lumbar punctures and pre-analytical sample handling should follow published consensus recommendations. The results must be interpreted in the context of the other available history information and assessments. Blood-based biomarkers and other non-invasive markers are expected to become available for clinical practice soon. Consequently, a broader usage of biomarkers is expected and may accelerate the development of individually tailored prevention and treatment approaches. This article provides the recommendations of the Swiss Memory Clinics for the use of biomarkers in clinical practice.